Valuation
- Market cap
- 16,808,000
- Revenue TTM
- $0
- Net income TTM
- $-8,300,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.06
Trading
- Volume
- 2,900
- Avg volume
- 8,750
- Day's range
- $2.79 – $2.87
- Shares out
- 5,776,000
- Stochastic %K
- 15%
- Beta
- 0.99
- Analysts
- Strong Buy
- Price target
- —
Company profile
NewcelX Ltd., a biopharmaceutical company, engages in developing transformative stem-cell-derived therapies for Diabetes. The company develops NCEL-101, a cellular therapy product based on enriched pancreatic islet-like clusters for the treatment of Type 1 diabetes and Type 2 insulin dependent diabetes; AstroRx, an off-the-shelf cryopreserved cell therapy product for the treatment of Amyotrophic Lateral Sclerosis and...
Show more
NewcelX Ltd., a biopharmaceutical company, engages in developing transformative stem-cell-derived therapies for Diabetes. The company develops NCEL-101, a cellular therapy product based on enriched pancreatic islet-like clusters for the treatment of Type 1 diabetes and Type 2 insulin dependent diabetes; AstroRx, an off-the-shelf cryopreserved cell therapy product for the treatment of Amyotrophic Lateral Sclerosis and neurodegenerative indications; and Dual Orexin-Receptor Agonist (DOXA), a small molecules platform for the treatment of sleep disorders, Neurodegenerative/ neuroinflammation diseases, and Diabetes Associated Neurological Disorders. It also develops iTOL-102, NCEL-201, NCEL-301, and NCEL-007. NewcelX Ltd. was founded in 2008 and is headquartered in Kloten, Switzerland.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 41 44 512 21 50
- Website
- https://newcelx.com
- Address
- Hohstrasse 1, Kloten, Switzerland
Latest news
No headlines yet.
